Jan. 15, 2020—Oxford Gene Technology launched its SureSeq CLL + CNV Panel, a next-generation sequencing panel designed to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia progression.
The panel offers copy number variation detection, including trisomy 12 and loss of heterozygosity, as well as somatic variants, even at low allele frequency. It can detect small and large CNVs at 10 percent minor allele frequency, SNVs, and indels down to one percent minor allele frequency and loss of heterozygosity at 5–10 Mb.
The SureSeq CLL + CNV Panel was designed in collaboration with recognized cancer experts, the company reports. “Having input from experienced cancer labs was instrumental in getting the design of the SureSeq CLL + CNV Panel spot on,” Emma Shipstone, executive vice president of marketing at OGT, said in a company press release. “This is CNV detection done well, yielding excellent data quality. This one assay can now replace the multiple assays historically necessary for the genomic profiling of CLL samples.”